Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.

ABSTRACT:

Objective

Bevacizumab has been shown to be effective in the treatment of recurrent glioblastoma in combination with chemotherapy compared with historic controls but not in randomized trials.

Methods

We conducted a retrospective analysis of patients treated for recurrent glioblastoma with bevacizumab vs a control group of patients, comparing progression-free survival (PFS) and overall survival (OS) between the two groups, and performed subgroup analysis based on age and performance status. Expression of vascular endothelial growth factor (VEGF) based on age was examined using DNA microarray analysis. We also evaluated the impact of bevacizumab on quality of life.

Results

We identified 44 patients who received bevacizumab and 79 patients who had not been treated with be

SUBMITTER: Nghiemphu PL 

PROVIDER: S-EPMC2677488 | biostudies-literature | 2009 Apr

REPOSITORIES: biostudies-literature